Literature DB >> 24166219

Desideratum for evidence based epidemiology.

J Marc Overhage1, Patrick B Ryan, Martijn J Schuemie, Paul E Stang.   

Abstract

BACKGROUND: There is great variation in choices of method and specific analytical details in epidemiological studies, resulting in widely varying results even when studying the same drug and outcome in the same database. Not only does this variation undermine the credibility of the research but it limits our ability to improve the methods.
METHODS: In order to evaluate the performance of methods and analysis choices we used standard references and a literature review to identify 164 positive controls (drug-outcome pairs believed to represent true adverse drug reactions), and 234 negative controls (drug-outcome pairs for which we have confidence there is no direct causal relationship). We tested 3,748 unique analyses (methods in combination with specific analysis choices) that represent the full range of approaches to adjusting for confounding in five large observational datasets on these controls. We also evaluated the impact of increasingly specific outcome definitions, and performed a replication study in six additional datasets. We characterized the performance of each method using the area under the receiver operator curve (AUC), bias, and coverage probability. In addition, we developed simulated datasets that closely matched the characteristics of the observational datasets into which we inserted data consistent with known drug-outcome relationships in order to measure the accuracy of estimates generated by the analyses. DISCUSSION: We expect the results of this systematic, empirical evaluation of the performance of these analyses across a moderate range of outcomes and databases to provide important insights into the methods used in epidemiological studies and to increase the consistency with which methods are applied, thereby increasing the confidence in results and our ability to systematically improve our approaches.

Mesh:

Year:  2013        PMID: 24166219     DOI: 10.1007/s40264-013-0102-2

Source DB:  PubMed          Journal:  Drug Saf        ISSN: 0114-5916            Impact factor:   5.606


  46 in total

1.  Randomized, controlled trials, observational studies, and the hierarchy of research designs.

Authors:  J Concato; N Shah; R I Horwitz
Journal:  N Engl J Med       Date:  2000-06-22       Impact factor: 91.245

Review 2.  Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins.

Authors:  Goodarz Danaei; Mohammad Tavakkoli; Miguel A Hernán
Journal:  Am J Epidemiol       Date:  2012-01-05       Impact factor: 4.897

3.  Design considerations in an active medical product safety monitoring system.

Authors:  Joshua J Gagne; Bruce Fireman; Patrick B Ryan; Malcolm Maclure; Tobias Gerhard; Sengwee Toh; Jeremy A Rassen; Jennifer C Nelson; Sebastian Schneeweiss
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-01       Impact factor: 2.890

Review 4.  Minimal and null predictive effects for the most popular blood biomarkers of cardiovascular disease.

Authors:  John P A Ioannidis; Ioanna Tzoulaki
Journal:  Circ Res       Date:  2012-03-02       Impact factor: 17.367

5.  Electronic healthcare databases for active drug safety surveillance: is there enough leverage?

Authors:  Preciosa M Coloma; Gianluca Trifirò; Martijn J Schuemie; Rosa Gini; Ron Herings; Julia Hippisley-Cox; Giampiero Mazzaglia; Gino Picelli; Giovanni Corrao; Lars Pedersen; Johan van der Lei; Miriam Sturkenboom
Journal:  Pharmacoepidemiol Drug Saf       Date:  2012-02-08       Impact factor: 2.890

6.  Statisticians set sights on observational studies.

Authors:  Rabiya S Tuma
Journal:  J Natl Cancer Inst       Date:  2007-05-02       Impact factor: 13.506

7.  Empirical performance of the self-controlled case series design: lessons for developing a risk identification and analysis system.

Authors:  Marc A Suchard; Ivan Zorych; Shawn E Simpson; Martijn J Schuemie; Patrick B Ryan; David Madigan
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

8.  Alternative outcome definitions and their effect on the performance of methods for observational outcome studies.

Authors:  Christian G Reich; Patrick B Ryan; Martijn J Schuemie
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

9.  Use of statins and risk of fractures.

Authors:  T P van Staa; S Wegman; F de Vries; B Leufkens; C Cooper
Journal:  JAMA       Date:  2001-04-11       Impact factor: 56.272

Review 10.  Defining a reference set to support methodological research in drug safety.

Authors:  Patrick B Ryan; Martijn J Schuemie; Emily Welebob; Jon Duke; Sarah Valentine; Abraham G Hartzema
Journal:  Drug Saf       Date:  2013-10       Impact factor: 5.606

View more
  4 in total

1.  How Confident Are We about Observational Findings in Healthcare: A Benchmark Study.

Authors:  Martijn J Schuemie; M Soledad Cepeda; Marc A Suchard; Jianxiao Yang; Yuxi Tian; Alejandro Schuler; Patrick B Ryan; David Madigan; George Hripcsak
Journal:  Harv Data Sci Rev       Date:  2020-01-31

2.  Comment on: "Desideratum for evidence-based epidemiology".

Authors:  Sean Hennessy; Charles E Leonard
Journal:  Drug Saf       Date:  2015-01       Impact factor: 5.606

3.  Empirical confidence interval calibration for population-level effect estimation studies in observational healthcare data.

Authors:  Martijn J Schuemie; George Hripcsak; Patrick B Ryan; David Madigan; Marc A Suchard
Journal:  Proc Natl Acad Sci U S A       Date:  2018-03-13       Impact factor: 11.205

4.  Incidence of Exposure of Patients in the United States to Multiple Drugs for Which Pharmacogenomic Guidelines Are Available.

Authors:  Matthias Samwald; Hong Xu; Kathrin Blagec; Philip E Empey; Daniel C Malone; Seid Mussa Ahmed; Patrick Ryan; Sebastian Hofer; Richard D Boyce
Journal:  PLoS One       Date:  2016-10-20       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.